lifestyle.cleanweb.co

Author: InflaRx N.V.

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

May 6, 2026
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

May 6, 2026
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

May 5, 2026
InflaRx to Report First Quarter 2026 Results on May 7, 2026

May 5, 2026
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 4, 2026
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

May 2, 2026
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

May 1, 2026
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

May 1, 2026
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

April 29, 2026
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

April 29, 2026